Company Overview
Azitra, Inc. operates as an early-stage clinical biopharmaceutical entity focused on developing therapies for precision dermatology through the utilization of engineered proteins and topical live biotherapeutic products designed to treat skin diseases within the United States. The company's primary pipeline asset involves the development of ATR-04, which utilizes a genetically modified strain of S. epidermidis to target specific dermatological conditions. This biotechnology firm functions within the broader Healthcare sector, specifically the Biotechnology industry, a classification that typically implies a high degree of scientific innovation and reliance on regulatory approval processes for commercialization. The company currently maintains a market capitalization of $3.89M and employs a workforce of 13 individuals. These financial and operational metrics indicate that Azitra, Inc. is a micro-cap entity with a very small revenue footprint, suggesting it is in a pre-revenue or early-stage commercialization phase where capital allocation is heavily weighted toward research and development rather than profit generation or market expansion.
Financial Health
Azitra, Inc. reports revenue of N/A for the trailing twelve months, alongside a net income of $-10,955,370 and an EBITDA of $-10,828,596, revealing a significant gap between top-line activity and bottom-line profitability that highlights a cost structure dominated by operational expenses and research costs rather than revenue generation. The company generated free cash flow of $-6,947,441, indicating a negative cash conversion rate that limits financial flexibility and necessitates continuous external financing to sustain operations. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a figure that reflects the current lack of commercial revenue scale necessary to realize positive margin contributions typical of established biopharmaceutical businesses. On the balance sheet, the company holds $2.07M in cash against total debt of $422,077, resulting in a debt-to-equity ratio of 11.10, which suggests a highly leveraged position relative to equity but also indicates that total liabilities are covered by cash reserves. The current ratio stands at 2.83, signaling strong short-term liquidity as the company holds sufficient current assets to cover its current liabilities nearly three times over. Return on Equity is reported at -230.7% and Return on Assets at -110.7%, metrics that demonstrate significant negative returns on capital employed, reflecting the early-stage nature of the business where investment is not yet yielding positive financial returns for shareholders or asset holders.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is reported as -0.46, a metric that implies negative expected earnings in the coming period rather than a traditional valuation multiple based on profitability. The price-to-book ratio is 0.68, indicating that the market values the company at a discount to its book value, which is common for early-stage biotechnology firms where intangible assets and future pipeline potential may not be fully reflected on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are presented as N/A and -0.21 respectively, suggesting that standard valuation multiples are distorted by the company's negative earnings and lack of sales data. The stock has traded between a 52-week high of $2.67 and a 52-week low of $0.10, representing a wide trading range characteristic of volatile micro-cap securities. The beta value is -1.50, which is an anomalous figure for equities that suggests extreme price volatility and an inverse correlation to the broader market, meaning the stock tends to move significantly more than the market average but in potentially unpredictable directions.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is no historical growth trajectory available for comparison as the company is either in its inception phase or has recently transitioned to operations. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A or 0.0%, reflecting a strategy where all available earnings and capital are reinvested into research and development rather than distributed to shareholders. The absence of a dividend policy is consistent with the company's stage of development, where preserving cash reserves is prioritized over income generation for investors. The overall growth and income profile is characterized by a complete lack of historical growth data and zero income distribution, positioning the company purely as a speculative investment based on potential future therapeutic approvals rather than current financial performance or shareholder returns.